{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:06:18Z","timestamp":1757541978034},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00059-020-05012-z","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T16:03:00Z","timestamp":1609344180000},"page":"206-211","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heart and kidney disease: a\u00a0cardiovascular high-risk constellation"],"prefix":"10.1007","volume":"46","author":[{"given":"Stefan J.","family":"Schunk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thimoteus","family":"Speer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Fliser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"issue":"3","key":"5012_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2013.243","volume":"84","author":"KM Andrassy","year":"2013","unstructured":"Andrassy\u00a0KM (2013) Comments on \u201cKDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease\u201d. Kidney Int 84(3):622\u2013623","journal-title":"Kidney Int"},{"issue":"9889","key":"5012_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort\u00a0RT et\u00a0al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339\u2013352","journal-title":"Lancet"},{"issue":"3S1","key":"5012_CR3","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","volume":"73","author":"R Saran","year":"2019","unstructured":"Saran\u00a0R et\u00a0al (2019) US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 73(3S1):A7\u2013A8","journal-title":"Am J Kidney Dis"},{"issue":"9931","key":"5012_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","volume":"383","author":"A Ortiz","year":"2014","unstructured":"Ortiz\u00a0A et\u00a0al (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383(9931):1831\u20131843","journal-title":"Lancet"},{"issue":"12","key":"5012_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneph.2010.143","volume":"6","author":"TB Drueke","year":"2010","unstructured":"Drueke\u00a0TB, Massy\u00a0ZA (2010) Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 6(12):723\u2013735","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"5012_CR6","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/ndt\/gft080","volume":"28","author":"T Speer","year":"2013","unstructured":"Speer\u00a0T, Zewinger\u00a0S, Fliser\u00a0D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28(10):2456\u20132463","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"5012_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","volume":"38","author":"T Speer","year":"2013","unstructured":"Speer\u00a0T et al (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor\u20112. Immunity 38(4):754\u2013768","journal-title":"Immunity"},{"issue":"5","key":"5012_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1681\/ASN.2013050482","volume":"25","author":"T Speer","year":"2014","unstructured":"Speer\u00a0T et\u00a0al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J\u00a0Am Soc Nephrol 25(5):1073\u20131082","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"5012_CR9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jacc.2016.07.755","volume":"68","author":"EW Holy","year":"2016","unstructured":"Holy\u00a0EW et al (2016) Carbamylated low-density lipoproteins induce a\u00a0prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo. J\u00a0Am Coll Cardiol 68(15):1664\u20131676","journal-title":"J Am Coll Cardiol"},{"issue":"43","key":"5012_CR10","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehu111","volume":"35","author":"T Speer","year":"2014","unstructured":"Speer\u00a0T et al (2014) Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart\u00a0J 35(43):3021\u20133032","journal-title":"Eur Heart J"},{"issue":"11","key":"5012_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/ndt\/gfv358","volume":"31","author":"S Zewinger","year":"2016","unstructured":"Zewinger\u00a0S et al (2016) Innate immunity in CKD-associated vascular diseases. Nephrol Dial Transplant 31(11):1813\u20131821","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"5012_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41581-019-0118-7","volume":"15","author":"F Knauf","year":"2019","unstructured":"Knauf\u00a0F, Brewer\u00a0JR, Flavell\u00a0RA (2019) Immunity, microbiota and kidney disease. Nat Rev Nephrol 15(5):263\u2013274","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"5012_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11883-019-0794-6","volume":"21","author":"S Ali","year":"2019","unstructured":"Ali\u00a0S et\u00a0al (2019) Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr Atheroscler Rep 21(9):32","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"5012_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/ndt\/gft321","volume":"29","author":"F Verbeke","year":"2014","unstructured":"Verbeke\u00a0F et al (2014) A European renal best practice (ERBP) position statement on the kidney disease: improving global outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant 29(3):490\u2013496","journal-title":"Nephrol Dial Transplant"},{"issue":"22","key":"5012_CR15","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"SPRINT Research Group","year":"2015","unstructured":"SPRINT Research Group et al (2015) A randomized trial of intensive versus standard blood-pressure control. N\u00a0Engl J Med 373(22):2103\u20132116","journal-title":"N Engl J Med"},{"issue":"9","key":"5012_CR16","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","volume":"28","author":"AK Cheung","year":"2017","unstructured":"Cheung\u00a0AK et\u00a0al (2017) Effects of intensive BP control in CKD. J\u00a0Am Soc Nephrol 28(9):2812\u20132823","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"5012_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"ACCORD Study Group","year":"2010","unstructured":"ACCORD Study Group et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N\u00a0Engl J Med 362(17):1575\u20131585","journal-title":"N Engl J Med"},{"issue":"5","key":"5012_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie\u00a0X et al (2016) Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67(5):728\u2013741","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"5012_CR19","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried\u00a0LF et\u00a0al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N\u00a0Engl J Med 369(20):1892\u20131903","journal-title":"N Engl J Med"},{"issue":"10","key":"5012_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","volume":"123","author":"SW Tobe","year":"2011","unstructured":"Tobe\u00a0SW et\u00a0al (2011) Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123(10):1098\u20131107","journal-title":"Circulation"},{"issue":"3","key":"5012_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M13-2453","volume":"160","author":"M Tonelli","year":"2014","unstructured":"Tonelli\u00a0M, Wanner\u00a0C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members (2014) Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 160(3):182","journal-title":"Ann Intern Med"},{"issue":"10","key":"5012_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2016","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration et al (2016) Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a\u00a0meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4(10):829\u2013839","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4S","key":"5012_CR23","first-page":"S1","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4S):S1\u2013S115","journal-title":"Kidney Int"},{"issue":"4","key":"5012_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer\u00a0SC et al (2012) Benefits and harms of statin therapy for persons with chronic kidney disease: a\u00a0systematic review and meta-analysis. Ann Intern Med 157(4):263\u2013275","journal-title":"Ann Intern Med"},{"issue":"8","key":"5012_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"SEARCH Collaborative Group","year":"2008","unstructured":"SEARCH Collaborative Group et al (2008) SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N\u00a0Engl J Med 359(8):789\u2013799","journal-title":"N Engl J Med"},{"issue":"6","key":"5012_CR26","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth\u00a0PP et\u00a0al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397\u20131408","journal-title":"Kidney Int"},{"issue":"23","key":"5012_CR27","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan\u00a0DM et\u00a0al (2019) Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J\u00a0Am Coll Cardiol 73(23):2961\u20132970","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"5012_CR28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B et\u00a0al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"4","key":"5012_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner\u00a0C et\u00a0al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N\u00a0Engl J Med 375(4):323\u2013334","journal-title":"N Engl J Med"},{"issue":"15","key":"5012_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL et\u00a0al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"8","key":"5012_CR31","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1093\/ndt\/gfs052","volume":"27","author":"TC Turin","year":"2012","unstructured":"Turin\u00a0TC et\u00a0al (2012) Chronic kidney disease and life expectancy. Nephrol Dial Transplant 27(8):3182\u20133186","journal-title":"Nephrol Dial Transplant"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-05012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-020-05012-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-05012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T07:08:00Z","timestamp":1623308880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-020-05012-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5012"],"URL":"https:\/\/doi.org\/10.1007\/s00059-020-05012-z","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"7 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"S.J.\u00a0Schunk, T.\u00a0Speer and D.\u00a0Fliser declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}